Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infant formula counterfeits & terrorism

This article was originally published in The Tan Sheet

Executive Summary

FDA recently "became aware of infant formula that was tampered with that was used to fund al Quaeda operatives," FDA Associate Commissioner for Regulatory Affairs Steven Niedelman said at the Food & Drug Law Institute's Enforcement & Litigation Conference in Washington D.C. Sept. 23. "Terrorism has become a big issue for the agency and one that all firms need to take into account," he noted. House Energy & Commerce Committee Senior Counsel Alan Slobodin asserted two years ago that terrorist organizations often are financed through counterfeit trade of consumer products such as infant formula (1"The Tan Sheet" Oct. 8, 2001, In Brief)...

You may also be interested in...

FDA "National Security" Mission: Counterfeiting And Bioterrorism?

FDA should heighten its focus on product security to ensure counterfeiting does not take place, not only for consumer safety, but to cut off a source of income for terrorists, asserted House Energy & Commerce Committee Senior Counsel Alan Slobodin.

Setback For Athenex, Hanmi As CRL Requests New Trial

Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.

Chordia Looks To Forge Own Path In Oncology

Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts